Abstract
Salicylidene acylhydrazide group synthetic compounds ME0053, ME005 and ME0192 are known for their iron chelating properties and due to these properties they are primarily used for blocking the bacterial type 3 secretory virulence system. On the other side, targeting the metabolic pathways of iron can provide new tools for cancer prognosis and treatment. Therefore, in this study, considering their iron chelating function, the effects of the compounds ME0053, ME0055 and ME0192 were investigated in SH-SY5Y neuroblastoma cell line. Iron chelating compounds are generally known to be effective in tumor development and metastasis by targeting iron in the cell. They can exert this effect through molecules such as cyclin, CDKs, as well as signaling pathways such as PI3K/AKT and ERK/MAPK. For this reason, we analyzed the effect of the iron chelating compounds of ME0053, ME0055 and ME0192 on cell viability and proliferation rate both through ERK/MAPK and PI3K/AKT signal paths, and through the oncogenic Speedy/RINGO protein that is likely to have a regulatory effect on these two signaling pathways. Apoptosis was also investigated by measuring the amount of active caspase-3, an apoptotic marker. Along with the decrease observed in the Speed...Continue Reading
References
Sep 1, 1994·The New England Journal of Medicine·G M BrittenhamJ W Harris
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·M W Hentze, L C Kühn
Dec 30, 1998·The Journal of Nutrition·R S Eisenstein, K P Blemings
Dec 10, 1999·Proceedings of the National Academy of Sciences of the United States of America·R S HubertD E Afar
Jun 26, 2002·The Journal of Biological Chemistry·Kevin PruittChanning J Der
Mar 27, 2003·Cellular Immunology·Beom-Su KimChang-Duk Jun
Jul 2, 2003·Leukemia·F ChangJ A McCubrey
Oct 31, 2003·Cancer Cell·Ji LuoLewis C Cantley
Mar 17, 2004·Cancer Treatment Reviews·Juan Angel Fresno VaraManuel González-Barón
Apr 23, 2005·Infection and Immunity·R NordfelthM Elofsson
Jul 4, 2006·Current Opinion in Chemical Biology·Deborah T Hung, Eric J Rubin
May 2, 2007·Infection and Immunity·Anatoly SlepenkinEllena M Peterson
May 15, 2007·Oncogene·D M Owens, S M Keyse
May 15, 2007·Oncogene·A S DhillonW Kolch
May 15, 2007·Oncogene·P J Roberts, C J Der
May 17, 2008·Cancer Research·Azadeh GolipourLisa A Porter
Sep 5, 2008·Annual Review of Pathology·Nader Chalhoub, Suzanne J Baker
Jul 29, 2009·Infection and Immunity·Jai J TreeAndrew J Roe
Jul 5, 2011·The Journal of Biological Chemistry·Dai WangAndrew J Roe
Jan 21, 2012·Biochemical Society Transactions·Edita AksamitieneBoris N Kholodenko
Mar 20, 2012·Antioxidants & Redox Signaling·Angelica M MerlotDes R Richardson
Apr 3, 2012·Antioxidants & Redox Signaling·Zaklina KovacevicDes R Richardson
Apr 3, 2012·Cell·Chi V Dang
Nov 29, 2012·Molecular Pharmacology·Jing SunDes R Richardson
Mar 29, 2014·Nature·Pengda LiuWenyi Wei
Jan 17, 2015·Oncoscience·Dorota Lubanska, Lisa A Porter
May 28, 2019·Cancer Letters·Zhe CaoDeliang Cao